For Patients
You’re not alone. We’re developing new medicines to treat aggressive cancers that resist current treatments.
Our Approach
Cancer cells move and divide using microscopic motor proteins. Our therapy, MT-125, is designed to block these internal motors inside cells. The result? The STAR-GBM trial will assess the preclinical demonstration that MT-125 stops aggressive cancers in their tracks and triggers tumor cells' own stress responses to help the body safely eliminate them. The STAR-GBM trial will also validate our preclinical findings demonstrating that MT-125 also helps current therapies, like radiation treatment, work better.
Trial Initiation (Pre-enrollment)
Glioblastoma Clinical Trial (NCT07185880)
STAR-GBM is a Phase 1/2 study evaluating the safety, tolerability, drug levels (pharmacokinetics), and early signs of therapeutic activity of MT-125 in adults with newly diagnosed, IDH wildtype, MGMT unmethylated glioblastoma. MT-125 will be given together with standard radiotherapy on a schedule coordinated by the study team.
The trial is being conducted in collaboration with investigators at the Mayo Clinic, along with additional participating centers listed on ClinicalTrials.gov. If you or a loved one has been recently diagnosed with IDH wildtype, MGMT unmethylated glioblastoma, your neuro-oncologist can review the listing and discuss eligibility with you. If you may be eligible, your physician can connect you with a study coordinator. As more information becomes available, it will be provided here.
- Phase: Phase 1/2
- Status: Open for enrollment
- Intervention: MT-125 in combination with standard radiotherapy
- Condition: Newly diagnosed IDH wild-type, MGMT-unmethylated glioblastoma
- Eligibility: Adults 18 years or older (up to 36 participants)
- Identifiers: NCT07185880 · NCI-2026-00742
Official trial listings — the same STAR-GBM study, listed across public registries:
Participating Sites & Contacts
The STAR-GBM trial is open for enrollment at the following Mayo Clinic locations. Study statuses change often — please contact the Cancer Center Clinical Trials Referral Office at (855) 776-0015 for the most up-to-date information on possible participation.
Mayo Clinic — Jacksonville
Principal investigator: Wendy Sherman, M.D.
Status: Open for enrollment
Contact: Cancer Center Clinical Trials Referral Office
(855) 776-0015
Mayo Clinic — Rochester
Principal investigator: Ugur Sener, M.D.
Status: Open for enrollment
Contact: Cancer Center Clinical Trials Referral Office
(855) 776-0015
Mayo Clinic — Scottsdale/Phoenix
Principal investigator: Shannon Fortin Ensign, M.D., Ph.D.
Status: Open for enrollment
Contact: Cancer Center Clinical Trials Referral Office
(855) 776-0015
Our Values
Patient-First Design
Safety, relevance, and access are at the core of everything we do. We design our trials with patients in mind.
Mechanism-Led Decisions
Data over dogma. We follow the science and let evidence guide our development programs.
Transparency
Clear goals, clear readouts. We believe in honest communication with patients, partners, and the community.
Collaboration
Bringing together patient advocates, industry partners, clinical experts, and academic researchers to accelerate life-changing therapies.
About Glioblastoma
Glioblastoma is an extremely aggressive brain tumor in adults. Standard care often includes surgery when feasible, followed by radiation and the chemotherapy drug temozolomide. The trial is being conducted in collaboration with investigators at the Mayo Clinic, along with additional participating centers.
If you or a loved one has been recently diagnosed with IDH wildtype, MGMT unmethylated glioblastoma, your neuro-oncologist can review the listing and discuss eligibility with you. If you may be eligible, your physician can connect you with a study coordinator.
National Brain Tumor Society
Personalized support and education. Because every brain and CNS tumor diagnosis is unique, your care should be, too. NBTS provides easy-to-understand resources and one-on-one support to help you and your family navigate this journey. We encourage you to partner closely with your healthcare team to explore your options and choose the treatment path that is right for you.
Safety & Privacy
Patient safety and privacy are a top priority. Our studies follow FDA-authorized protocols with close monitoring for side effects, and personal health information is protected in accordance with applicable laws and site policies. Participation is voluntary, and you may withdraw at any time after speaking with your care team. If you or a loved one is not eligible for a clinical trial, you can learn more about potential pathways to access investigational treatment through our Expanded Access program.
Frequently Asked Questions
What is MT-125?
MT-125 is an investigational therapy designed to block the myosin motor proteins that cancer cells use to move and divide. It is given together with standard radiotherapy because it is also designed to help radiotherapy work better. This is the first time MT-125 is being studied in humans, so its use is considered investigational.
Who can take part in the STAR-GBM trial?
The study is enrolling adults 18 years or older with newly diagnosed, histologically and/or molecularly confirmed IDH wild-type, MGMT-unmethylated glioblastoma. Up to 36 participants will be enrolled. Final eligibility is determined by the study team after screening tests.
Where can I enroll in the STAR-GBM trial?
The trial is open for enrollment at Mayo Clinic in Jacksonville, Florida; Rochester, Minnesota; and Scottsdale/Phoenix, Arizona. You can reach the Cancer Center Clinical Trials Referral Office at (855) 776-0015 for the most up-to-date information.
What is the STAR-GBM trial evaluating?
The Phase 1/2 study evaluates the safety, tolerability, pharmacokinetics, and early signs of therapeutic activity of MT-125 in adults with newly diagnosed glioblastoma. The initial dose-escalation phase gives different doses of MT-125 with radiotherapy to identify the highest tolerated dose.
How can I get more information about the trial?
Review the official listings on ClinicalTrials.gov (NCT07185880), Mayo Clinic, and the National Cancer Institute (NCI-2026-00742), and discuss eligibility with your neuro-oncologist. Physicians who would like to speak with Myosin Therapeutics can contact us through the form below.
Support Our Research
Every contribution, large or small, helps accelerate first-in-class therapies targeting molecular nanomotors in cancer and neurological disease.